不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
皮肤 T 细胞淋巴瘤（CTCL）新型系统性治疗进展
英文原题：Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL).
查看英文原题
Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL).
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
综述目的：皮肤T细胞淋巴瘤（CTCL）是一组异质性非霍奇金淋巴瘤，治疗困难，且常对标准治疗耐药。蕈样肉芽肿（MF）和Sézary综合征（SS）是最常见亚型，占多数CTCL病例。目前没有标准治疗，也没有治愈性疗法。本综述总结近期报道的、用于MF/SS管理的新型全身药物的有希望数据。近期发现：临床试验正在研究多种药物，包括新型化疗药物、抗体及抗体药物偶联物（ADC）、免疫疗法和细胞疗法。这些有前景的新药可能拓展MF/SS的治疗选择。
展开英文摘要原文
PURPOSE OF REVIEW: Cutaneous T cell lymphomas (CTCLs) are comprised of a heterogenous group of non-Hodgkin lymphomas that can be difficult to treat and are often refractory to standard therapies. Mycosis fungoides (MF) and Sezary syndrome (SS) are the most common subtypes, accounting for the majority of CTCLs. There is no standard of care, and no treatments are curative.
In this review, we summarize the promising, recently reported data describing novel systemic agents for the management of MF/SS. RECENT FINDINGS: Clinical trials are currently exploring a number of agents, including novel chemotherapies, antibodies and antibody drug conjugates (ADCs), immunotherapy, and cellular therapies. These promising novel agents may expand the treatment landscape for MF/SS.
论文信息
- 作者
- Case KB、Allen PB
- 第一作者单位
- Emory University School of Medicine, Atlanta, GA, USA.United States
- 通讯作者单位
- Department of Hematology, Winship Cancer Institute, Atlanta, GA, USA. pamela.b.allen@emory.edu.United States
- 文献类型
- 综述
- 期刊
- Current hematologic malignancy reports2025 Jan 13
- 原文标识
- PubMed 39800801 · DOI 10.1007/s11899-024-00746-7